Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Facto...
December 13 2017 - 6:30PM
Business Wire
- Bristol-Myers Squibb to develop and
commercialize ONO-4578, Ono’s Phase 1 selective Prostaglandin E2
(PGE2) receptor 4 (EP4) antagonist
- Strengthens Bristol-Myers Squibb’s
oncology development program with potential to expand and enhance
the benefit of immunotherapy in a broad range of tumor
indications
- Expands companies’ Immuno-Oncology
alliance established in 2014
Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical
Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo
Sagara; “Ono”) announced an agreement that grants Bristol-Myers
Squibb an exclusive license for the development and
commercialization of ONO-4578, Ono’s selective Prostaglandin E2
(PGE2) receptor 4 (EP4) antagonist. The companies will also
collaborate on discovery efforts to identify additional compounds
from Ono’s PGE2 receptor antagonist programs.
“To improve long-term outcomes for more patients with cancer, we
believe more Immuno-Oncology based combinations may be required,
and we are pleased to continue our long-standing collaboration with
Ono with this focus in mind,” said Fouad Namouni, M.D., head of
Development, Oncology, Bristol-Myers Squibb. “Ono’s Prostaglandin
E2 receptor antagonist programs offer the potential to develop
targeted therapies that counteract the effects of an
immunosuppressive tumor microenvironment. Researching Prostaglandin
E2 receptor antagonists in combination with our oncology portfolio
has the potential to result in an enhanced response in a broad
range of tumors.”
“We are very pleased to collaborate with Bristol-Myers Squibb on
ONO-4578, an innovative Immuno-Oncology therapy candidate derived
from our long-standing Prostaglandin projects, and to further work
with Bristol-Myers Squibb on other Prostaglandin E2 receptor
antagonist programs,” said Hiroshi Awata, Vice President Executive
Officer and Executive Director, Clinical Development, Ono
Pharmaceutical Co., Ltd. “We are committed to further pursuing the
worldwide development of ONO-4578 with Bristol-Myers Squibb with
the goal of improving outcomes of patients suffering from cancer
around the world as promptly as possible.”
Under the terms of the agreement, Bristol-Myers Squibb will make
an upfront payment of $40 million to Ono. Bristol-Myers Squibb will
be solely responsible for the development, manufacturing and
commercialization of ONO-4578 as well as other PGE2 receptor
antagonist products in all countries of the world except Japan,
South Korea, Taiwan, China and Association of Southeast Asian
Nations (ASEAN) countries. Ono is eligible to receive subsequent
clinical, regulatory and sales-based milestone payments, as well as
royalties in these countries where Bristol-Myers Squibb has
exclusive license. In Japan, South Korea and Taiwan, Bristol-Myers
Squibb and Ono will partner on the development and
commercialization under the companies’ existing collaboration
agreement, while in China and ASEAN countries, Ono will retain
exclusive rights.
About Prostaglandin
E2 and Immuno-Oncology
Prostaglandin E2 (PGE2), a major immunosuppressive factor in the
tumor microenvironment, is believed to suppress tumor immunity and
promote tumor progression. Preclinical data suggests that
modulation of PGE2 through any PGE2 receptor antagonists may
complement Immuno-Oncology therapies, including anti-PD-1 and
anti-CTLA-4, and potentially increase both the rate and durability
of response in tumors that are refractory to immunotherapy. Certain
patients and tumor types have higher expression of PGE2-related
molecules and/or immune characteristics that are more likely to
respond to PGE2 receptor blockade, presenting an opportunity for
patient stratification to improve outcomes.
About ONO-4578
ONO-4578 is a selective, oral antagonist of EP4, which is a
Prostaglandin E2 receptor. In results from experiments using mouse
models, ONO-4578 showed an anti-tumor effect by improving
immunosuppressive tumor microenvironment. Ono has already commenced
Phase I clinical study of ONO-4578 in Japan.
About the Bristol-Myers Squibb and Ono
Pharmaceutical Collaboration
In 2011, through a collaboration agreement with Ono
Pharmaceutical Co., Ltd., Bristol-Myers Squibb expanded its
territorial rights to develop and commercialize Opdivo globally
except in Japan, South Korea and Taiwan, where Ono had retained all
rights to the compound at the time. On July 23, 2014, Ono and
Bristol-Myers Squibb further expanded the companies’ strategic
collaboration agreement to jointly develop and commercialize
multiple immunotherapies – as single agents and combination
regimens – for patients with cancer in Japan, South Korea and
Taiwan.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on
LinkedIn, Twitter, YouTube and Facebook.
About Ono Pharmaceutical Co.,
Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is
an R&D-oriented pharmaceutical company committed to creating
innovative medicines in specific areas, especially in oncology and
diabetes areas. For more information, please visit the company’s
website at http://www.ono.co.jp/eng/index.html.
Bristol-Myers Squibb Forward-Looking
Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development, and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that ONO-4578 or any other compounds from the PGE2 receptor
programs will be successfully developed or approved for any of the
indications described in this release. Forward-looking statements
in this press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2016, in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171213005815/en/
Bristol-Myers Squibb:Media:Ken Dominski,
609-252-5251ken.dominski@bms.comorInvestor:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorOno
Pharmaceutical:Corporate
Communicationspublic_relations@ono.co.jp
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024